MADISON HEIGHTS, Mich., May 5 /PRNewswire-FirstCall/ -- InfuSystem Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced financial results and provided a business update for the first quarter ended March 31, 2009.
Mr. Steve Watkins, chief executive officer, commented, "We achieved $9.2 million of revenue during the first quarter of 2009, despite a nationwide shortage of Leucovorin, a compound frequently used in association with ambulatory pump chemotherapy, which has since been resolved. At the same time, we increased gross margins by 560 basis points and continue to gain operating leverage as we held our costs in line. As a result, we generated $2.9 million of adjusted EBITDA, a 45% increase compared to the first quarter of 2008. This contributed to the Company's continued strong operating cash flow and ample cash reserves, allowing us to improve the balance sheet by aggressively paying down debt. Shortly following the first quarter, we made a $5.3 million payment on our term loan, resulting in the Company having lowered its term loan balance by over $6.1 million year-to-date."
Mr. Watkins concluded, "We remain encouraged by the near- and long-term outlook for the ambulatory infusion services market. Drug companies are incorporating continuous infusion as part of their drug treatment regimens and promoting these to oncologists. The American Cancer Society estimated that there were about 148,810 new cases of colorectal cancer in 2008 in the United States. Moreover, the combined benefits to the patient, physician and insurance provider support the expanded use of ambulatory infusion pumps to administer chemotherapy beyond stage III colorectal cancer, including esophageal, head and neck, gastric and other cancers. In order to best capitalize on this market opportunity, we continue to enhance our sales organization, including the recent addition of Bryan Russo as chief commercial officer. We look forward to his contributions as we focus on accelerating and deepening our penetration of oncology practices nationwide. Looking ahead, we anticipate continued organic revenue growth, greater operational efficiencies, and continued strong cash flow to allow for paying down additional debt in 2009."
Revenue for the first quarter ended March, 31 2009 was $9.2 million, an 8.2% improvement compared to $8.5 million for the same period in 2008. The increase in revenue was primarily due to obtaining business at new customer facilities, increased reimbursement, as well as improved collection efficiencies. Operating income for the first quarter of 2009 was $1.3 million versus operating income of $521,000 for the same period in 2008. The increase in operating income for the first quarter of 2009 was due, in part, to increased sales and lower product and supply costs, which were partially offset by an increase in selling and marketing expenses.
The net loss for the first quarter of 2009 was ($2.5 million), or $(0.14) per diluted share, compared to net income of $4.8 million or $0.29 per diluted share, for the same period in 2008. The net income for the first quarter of 2009 included a ($2.6 million) loss on derivative financial instruments, which was predominantly attributable to the increase in the publicly traded value of the Company's warrants during the quarter, compared to a $5.2 million gain for the first quarter of 2008.
Adjusted EBITDA for the first quarter ended March 31, 2009 was $2.9 million, compared to $2.0 million for the same period in 2008. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, and excludes gain (loss) on derivative financial instruments and stock-based compensation. Adjusted EBITDA is not a measure of performance calculated in accordance with generally accepted accounting principles in the United States ("GAAP"). The Company believes the presentation of Adjusted EBITDA is a relevant and useful measure to assist a reader's ability to understand the Company's operating performance. The Company's management likewise utilizes Adjusted EBITDA as a means to measure its operating performance. The table below reconciles Adjusted EBITDA, a non-GAAP measure, to net income.
Three Months Ended Reconciliation from Net March 31 Income to Adjusted EBITDA: 2009 2008 Net Income $(2,507) $4,797 Adjustments: Interest expense 989 958 Interest income (3) (3) Income tax expense 140 - Depreciation -- Pumps 840 963 Depreciation -- Other 32 41 Amortization 457 457 EBITDA $(52) $7,213 Adjustments: Loss (gain) on derivatives 2,642 (5,231) Stock based compensation 278 - Adj. EBITDA $2,868 $1,982
About InfuSystem Holdings, Inc.
InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.
INFUSYSTEM HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS March 31, December 31, (in thousands, except share data) 2009 2008 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $11,358 $11,513 Accounts receivable, less allowance for doubtful accounts of $1,680 and $1,552 at March 31, 2009 and December 31, 2008, respectively; March 31, 2009 and December 31, 2008 include $121 and $72 due from I-Flow, respectively 4,636 4,168 Inventory supplies 432 391 Prepaid expenses and other current assets 1,026 676 Total Current Assets 17,452 16,748 Property & equipment, net 10,833 10,878 Deferred debt issuance costs, net 1,133 1,276 Goodwill 56,580 56,580 Intangible assets, net 30,282 30,738 Total Assets $116,280 $116,220 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $1,368 $1,012 Deferred income taxes 55 55 Other current liabilities 1,069 939 Derivative liabilities 5,235 2,592 Current portion of long-term debt; both March 31, 2009 and December 31, 2008 include $8,564 payable to I-Flow 8,645 8,644 Total Current Liabilities 16,372 13,242 Long-term debt, net of current portion; March 31, 2009 and December 31, 2008 include $20,868 and $21,685 payable to I-Flow, respectively 21,185 22,025 Deferred income taxes 880 880 Total Liabilities $38,437 $36,147 Stockholders' Equity Preferred stock, $.0001 par value: authorized 1,000,000 - - shares; none issued Common stock, $.0001 par value; authorized 200,000,000 shares; issued 18,537,671 and 18,512,671, respectively; outstanding 18,537,671 and 17,278,626, respectively 2 2 Additional paid-in capital 81,069 80,792 Retained deficit (3,228) (721) Total Stockholders' Equity 77,843 80,073 Total Liabilities and Stockholders' Equity $116,280 $116,220 INFUSYSTEM HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended March 31 (in thousands, except per share data) 2009 2008 Net revenues $9,227 $8,530 Operating expenses: Cost of Revenues -- Product and supply costs 1,270 1,465 Cost of Revenues -- Pump depreciation 840 963 Provision for doubtful accounts 969 861 Amortization of intangibles 457 457 Selling and marketing 1,320 1,077 General and administrative 3,110 3,186 Total Operating Expenses 7,966 8,009 Operating income 1,261 521 Other (loss) income: (Loss) gain on derivatives (2,642) 5,231 Interest income 3 3 Interest expense (989) (958) Total other (loss) income (3,628) 4,276 (Loss) income before income taxes (2,367) 4,797 Income tax expense (140) - Net (loss) income (2,507) 4,797 Net (loss) income per share: Basic & Diluted (0.14) 0.29 Weighted average shares outstanding: Basic & Diluted 18,531,838 16,824,295 INFUSYSTEM HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Three Months Ended March 31 (in thousands) 2009 2008 OPERATING ACTIVITIES Net (Loss) Income (2,507) 4,797 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Loss (gain) on derivative liabilities 2,642 (5,231) Provision for doubtful accounts 969 861 Depreciation 872 1,004 Amortization of intangible assets 457 457 Amortization of deferred debt issuance costs 143 180 Loss on disposal of assets 109 225 Stock-based compensation 278 - Changes in current assets and liabilities: (Increase) decrease in accounts receivable, net of provision (1,437) 187 (Increase) decrease in prepaid expenses and other current assets (391) 803 Increase in accounts payable and other current liabilities 134 140 NET CASH PROVIDED BY OPERATING ACTIVITIES 1,269 3,423 INVESTING ACTIVITIES Payment of deferred acquisition costs - (97) Capital expenditures (586) (447) Proceeds from sale of property 1 - NET CASH USED IN INVESTING ACTIVITIES (585) (544) FINANCING ACTIVITIES Principal payments on term loan (818) (409) Principal payments on capital lease obligation (21) - NET CASH USED IN FINANCING ACTIVITIES (839) (409) Net change in cash and cash equivalents (155) 2,470 Cash and cash equivalents, beginning of period 11,513 3,960 Cash and cash equivalents, end of period 11,358 6,430
|SOURCE InfuSystem Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved